Levocarnitine in Treating Fatigue in Cancer Patients
Phase III Randomized Placebo-Controlled Trial to Determine Efficacy of Levocarnitine for Fatigue in Patients With Cancer
Sponsor: ECOG-ACRIN Cancer Research Group
Listed as NCT00091169, this PHASE3 trial focuses on Fatigue and Unspecified Adult Solid Tumor, Protocol Specific and remains completed. Sponsored by ECOG-ACRIN Cancer Research Group, it has been updated 8 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Aug 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Aug 2023 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Dec 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- ECOG-ACRIN Cancer Research Group
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Abington, United States, Ann Arbor, United States, Aurora, United States, Bloomington, United States, Boca Raton, United States, Brooklyn, United States, Bryn Mawr, United States, Burnsville, United States, Canton, United States, Carthage, United States and 77 more location s